Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 21, 2025
Editor's Commentary
Solving CNS delivery will open big doors for epigenome editing: a Perspective
Epigenome editors could shine in neurology indications not served by other modalities — but only if companies invest in delivery
BioCentury | Mar 4, 2025
Product Development
CRISPR lessons; plus AbbVie enters obesity — a BioCentury podcast
BioCentury’s editors also discuss recommendations for early stage rare disease drug development
BioCentury | Feb 28, 2025
Product Development
Intellia: Balancing in vivo risk with validated targets
Sticking with genetic targets validated by Alnylam and Ionis gave Intellia confidence to take CRISPR in vivo
BioCentury | Feb 28, 2025
Product Development
Caribou: Solving the allogeneic problem with CRISPR
Caribou selected a de-risked target and modality to take on multiplexed editing
BioCentury | Feb 27, 2025
Product Development
Editas: The high-risk, high-reward gene editing pioneer
Editas set out to bring a new technology — CRISPR-Cas9 — to indications not served by existing therapeutic modalities
BioCentury | Feb 27, 2025
Product Development
Crispr Therapeutics: Controlled risk for accelerated development
An ex vivo gene knockout approach helped the company become first to market with a gene editing therapy
BioCentury | Feb 26, 2025
Distillery Therapeutics
Inhibition of cancer cell NDUFS4 for antitumor immunity
BioCentury | Feb 25, 2025
Product Development
Indication selection: Lessons learned from the CRISPR-Cas9 story
Founding CEOs of gene editing companies discuss their pipeline strategies and lessons learned
BioCentury | Jan 28, 2025
Distillery Therapeutics
Inhibiting polyunsaturated fatty acid metabolism for metastasis
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New modality showdowns
Genetic therapies compete in the same indications, as degraders come of age
Items per page:
1 - 10 of 737